Positive phase I results for Meiji’s ustekinumab biosimilar

Biosimilars/Research | Posted 04/06/2021 post-comment0 Post your comment

Japan-based Meiji Seika Pharma (Meiji) announced on 21 May 2021 positive phase I results for its candidate ustekinumab biosimilar, DMB-3115.

106 MD002160

Ustekinumab is a humanized monoclonal antibody that interferes with the triggering of the body’s inflammatory response through the suppression of certain cytokines. Specifically, it blocks interleukin IL 12 and IL 23 which help activate certain T-cells. It binds to the p 40 subunit of both IL 12 and IL 23 so that they subsequently cannot bind to their receptors. It is indicated for the treatment of Crohn’s disease, psoriasis and psoriatic arthritis.

The phase I study is a randomized double-blind, three-arm, single-dose study to compare the pharmacokinetics, safety and tolerability of DMB-3115 with its reference products (US- and EU-marketed products) in 296 healthy volunteers at a single site in Europe.

Meiji reports that the results of the study demonstrate ‘bioequivalence of DMB-3115 compared to reference products’ … ‘in terms of several pharmacokinetic parameters’. They add that ‘a single subcutaneous injection of DMB[-]3115 in healthy volunteers was well tolerated’ and that ‘the reported adverse events corresponded with the known safety profile of ustekinumab’. According to Meiji, there were also ‘no new unexpected adverse events’.

Meiji also announced the initiation of a phase III multi-regional clinical trial (NCT04785326: Opportuniti) in patients with plaque psoriasis. The phase III trial will study the efficacy, safety and immunogenicity of subcutaneous DMB-3115 versus originator ustekinumab (Stelara) in patients with moderate to severe chronic plaque psoriasis. The trial is currently recruiting. It plans to enrol 590 patients and is expected to be completed in November 2022.

Related articles
Trials of ustekinumab biosimilars advance

Biosimilars of ustekinumab


To further enhance the objectives of GaBI in sharing information and knowledge that ensure policies supportive of safe biosimilars use, we are pleased to announce that we will be launching a new section on GaBI Online and GaBI Journal, the ‘Latin American Forum’ (in Spanish) featuring the latest news and updates on research and developments in generic and biosimilar medicines in Latin America.

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.



Para fomentar los objetivos de GaBI sobre la difusión de información y conocimiento sobre las políticas de apoyo que garantizan el uso seguro de medicamentos biosimilares, nos complace anunciar el lanzamiento de una nueva sección en GaBI Online y GaBI Journal, el ‘Latin American Forum’ (en español), que presentará las últimas noticias y actualizaciones en investigación y desarrollo sobre medicamentos genéricos y biosimilares en Latinoamérica.

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

Source: ClinicalTrials.gov, Meiji Seika Pharma

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010